Beam Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle...
Latest News
4 days ago · seekingalpha.com
Beam Therapeutics: Market Selling Promising Data Readouts Doesn't Add UpBeam Therapeutics receives a Buy rating, driven by promising data across AATD, GSDIa, and SCD, and robust funding. BEAM's risto-cel SCD therapy shows strong efficacy but faces market skepticism due to challenging treatment regimens and competition. The company's in-vivo gene editing pipeline, especially BEAM-302 in AATD, is viewed as the primary value driver amid industry doubts.
5 days ago · zacks.com
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD StudyBeam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.
6 days ago · globenewswire.com
Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell DiseaseBEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary Safety Endpoints at the Prespecified Interim Analysis Study Met All Secondary Endpoints Including Freedom from Inpatient Hospitalization for Severe VOCs for 12 Consecutive Months Results Support Planned U.S. Biologics License Application (BLA) Submission for risto-cel, Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced positive topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).
14 days ago · zacks.com
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue EstimatesBeam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $1.1 per share a year ago.
18 days ago · zacks.com
3 Promising Genomics Stocks to Add to Your Portfolio NowGenomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
19 days ago · zacks.com
Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
21 days ago · seekingalpha.com
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a TranscriptBeam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a Transcript
21 days ago · marketbeat.com
Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting ToleranceBeam Therapeutics NASDAQ: BEAM reported initial clinical data from its Phase I/II trial of BEAM-301, an investigational base-editing therapy for glycogen storage disease type 1A (GSD1a), showing dose-dependent improvements in fasting tolerance and reductions in cornstarch supplementation among the first six treated patients.
21 days ago · globenewswire.com
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual CongressIn the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment Safety Profile of BEAM-301 Consistent with LNP-Based Therapies Beam Plans to Engage FDA on Potential Path to Approval; Enrollment in 60 mg Dose Cohort Underway Company to Host Investor Webcast Today, October 27, 2026, at 8:00 a.m. ET CAMBRIDGE, Mass.
1 month ago · fool.com
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Cathie Wood owns Beam shares worth roughly $220 million, at the stock's current price. All of the company's revenue is collaboration revenue.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BEAM